SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling

Jun Sheng; Mengchen Yin; Zhengwang Sun; Xia Kang; Da Liu; Kai Jiang; Jia Xu; Feixing Zhao; Qunfeng Guo; Wei Zheng

doi:10.18632/oncotarget.22167

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling

Jun Sheng, Mengchen Yin, Zhengwang Sun, Xia Kang, Da Liu, Kai Jiang, Jia Xu, Feixing Zhao, Qunfeng Guo and Wei Zheng _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:105276-105283. https://doi.org/10.18632/oncotarget.22167

Metrics: PDF 1288 views | HTML 1959 views | ?

Abstract

Jun Sheng1,*, Mengchen Yin2,*, Zhengwang Sun3,*, Xia Kang1, Da Liu1, Kai Jiang1, Jia Xu4,**, Feixing Zhao5,**, Qunfeng Guo3,** and Wei Zheng1,**

1Department of Orthopedics, Chengdu Military General Hospital, Chengdu, Sichuan, China

2Department of Orthopedics, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

3Department of Orthopedics, Changzheng Hospital, The Second Military Medical University, Shanghai, China

4Department of Personnel Office, Traditional Chinese Medical Hospital of Zhuji, Zhuji, Zhejiang, China

5Department of Pathology, Zhuji People’s Hospital of Zhejiang Province, Zhuji, Zhejiang, China

*These authors have contributed equally to this work

**Authors for correspondence with equal contribution

Correspondence to:

Wei Zheng, email: [email protected]

Jia Xu, email: [email protected]

Feixing Zhao, email: [email protected]

Qunfeng Guo, email: [email protected]

Zhengwang Sun, email: [email protected]

Keywords: SPC24; osteosarcoma; Ras/Raf/MEK/ERK signal pathway; E-cadherin

Received: April 19, 2017 Accepted: August 29, 2017 Published: October 27, 2017

ABSTRACT

In this study, we investigated the role of the spindle checkpoint protein SPC24 in osteosarcoma progression. SPC24 knockdown in 143B and U2OS osteosarcoma cells decreased cell growth, survival and invasiveness. The SPC24 knockdown cells also exhibited low EGFR, Ras and phospho-ERK levels and high E-cadherin levels, suggesting inhibition of EGFR/Ras/ERK signaling and epithelial-to-mesenchymal transitioning. Xenografted SPC24 knockdown osteosarcoma cells showed reduced tumor growth in nude mice with decreased EGFR and phospho-ERK levels and increased E-cadherin levels. By contrast, human osteosarcoma tissue samples showed high SPC24 and phospho-ERK levels and low E-cadherin levels. These results suggest SPC24 promotes osteosarcoma progression by increasing EGFR/Ras/ERK signaling.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22167

Publication Alerts

Research Papers:

SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling

Abstract